Market Overview

UPDATE: Credit Suisse Upgrades Medtronic to Outperform on Growth Outlook

Share:
Related MDT
What Specific Role Will Apple Play In IBM's Watson Health Cloud Alliance?
The Big Health Data Orgy Happening In The Cloud
A Dividend Growth Leaders Portfolio With A 17.5% Dividend Growth Rate (Seeking Alpha)

Credit Suisse upgraded Medtronic (NYSE: MDT) from Neutral to Outperform and raised the price target from $47.00 to $50.00.

Credit Suisse noted, "MDT's F2H13 & F14 growth aspirations indicate increased confidence that the last 2 quarters of ~5% WW CC growth represent sustainable improvement relative to the flattish top-line growth reported in FY11 & FY12 and further suggest that the growth-oriented acquisitions (Peak, Salient, KH) and increased emerging markets focus that have taken place during CEO Omar Ishrak's early tenure with the company are moving MDT in the right strategic direction."

Medtronic closed at $43.94 on Wednesday.

Latest Ratings for MDT

DateFirmActionFromTo
Mar 2015BMO CapitalMaintainsOutperform
Feb 2015JefferiesMaintainsBuy
Dec 2014Bank of AmericaMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...